Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial

Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association
Alla B GuekhtCerebrolysin Investigators

Abstract

No drug to treat vascular dementia (VaD) has yet been approved by the American or European authorities, leaving a large population of patients without effective therapy. Cerebrolysin has a long record of safety and might be efficacious in this condition. We conducted a large, multicenter, double-blind, placebo-controlled study in 242 patients meeting the criteria for VaD. The primary endpoint was the combined outcome of cognition (based on Alzheimer's Disease Assessment Scale Cognitive Subpart, Extended Version [ADAS-cog+] score) and overall clinical functioning (based on Clinician's Interview-Based Impression of Change plus Caregiver Input [CIBIC+] score) assessed after 24 weeks of treatment. Intravenous Cerebrolysin 20 mL was administered once daily over the course of 2 treatment cycles as add-on therapy to basic treatment with acetylsalicylic acid. The addition of Cerebrolysin was associated with significant improvement in both primary parameters. At week 24, ADAS-cog+ score improved by 10.6 points in the Cerebrolysin group, compared with 4.4 points in the placebo group (least squares mean difference, -6.17; P < .0001 vs placebo). CIBIC+ showed a mean improvement of 2.84 in the treatment arm and 3.68 in the placebo arm, a tr...Continue Reading

References

Dec 1, 1985·Archives of Gerontology and Geriatrics·W D Oswald, U M Fleischmann
Jan 1, 1995·Neuroepidemiology·R Hébert, C Brayne
Dec 28, 1999·Alzheimer Disease and Associated Disorders·W A Rocca, E Kokmen
Dec 14, 2002·Annals of the New York Academy of Sciences·Amos D Korczyn
Apr 14, 2005·Journal of Clinical Psychology·Bruce E WampoldKuldhir S Bhati
Jul 2, 2005·Neuroimmunomodulation·France Haour
May 3, 2006·Cerebrovascular Diseases·Eduardo Martínez-VilaPablo Irimia
Aug 21, 2007·Lancet Neurology·Amos D Korczyn
Dec 1, 2007·Clinical Interventions in Aging·Catherine McVeigh, Peter Passmore
Feb 6, 2008·Topics in Stroke Rehabilitation·Michael J Schneck

❮ Previous
Next ❯

Citations

Apr 30, 2014·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Natan M BornsteinAmos D Korczyn
Apr 5, 2012·Journal of the Neurological Sciences·Ingmar SkoogAlla Guekht
Feb 27, 2013·The Cochrane Database of Systematic Reviews·Ning ChenLi He
Feb 27, 2013·The Cochrane Database of Systematic Reviews·Virginia WongVanessa Chu
Nov 12, 2019·The Cochrane Database of Systematic Reviews·Shuhui CuiLi He
Dec 12, 2019·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·A N Bogolepova
Dec 19, 2019·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·M V Putilina
Aug 30, 2019·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·O S Levin, E E Vasenina
Oct 18, 2000·The Cochrane Database of Systematic Reviews·P S WilliamsA Spector
May 5, 2000·The Cochrane Database of Systematic Reviews·P S WilliamsG Rands
Dec 20, 2020·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·O S Levin, A N Bogolepova
Jan 31, 2021·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Brian FianiErika Sarno

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.